2-(4-formylphenyl)-1H-benzoimidazole-4-carboxylic acid amide | 711007-47-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(4-formylphenyl)-1H-benzoimidazole-4-carboxylic acid amide
• 英文别名: 2-(4-formylphenyl)-1H-benzimidazole-4-carboxamide
• CAS: 711007-47-5
• 化学式: C₁₅H₁₁N₃O₂
• 分子量: 265.271
• InChiKey: SYASDUNCVREXGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  88.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-formylphenyl)-1H-benzoimidazole-4-carboxylic acid amide 在 sodium tetrahydroborate 、 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 乙醇 、 乙腈 为溶剂， 生成 2-(4-Chloromethyl-phenyl)-1H-benzoimidazole-4-carboxylic acid amide
  参考文献：
  名称：

  Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors

  摘要：

  The synthesis and biological evaluation of a new series of amine-substituted 2-arylbenzimidazole-4-carboxamide inhibitors of the DNA-repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) is reported. The introduction of an amine substituent at the 2-aryl position is not detrimental to activity, with most inhibitors exhibiting K-i values for PARP-1 inhibition in the low nanomolar range. Two compounds in this series were found to potentiate the cytotoxicity of the DNA-methylating agent temozolomide by 4-5-fold in a human colorectal cancer cell line. (C) 2004 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2004.03.017
• 作为产物：
  描述：

  2-氨基-3-硝基苯甲酰胺 在 palladium on activated charcoal 盐酸 、 氢气 、 sodium hydrogensulfite 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基乙酰胺 为溶剂， 反应 5.0h， 生成 2-(4-formylphenyl)-1H-benzoimidazole-4-carboxylic acid amide
  参考文献：
  名称：

  Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors

  摘要：

  The synthesis and biological evaluation of a new series of amine-substituted 2-arylbenzimidazole-4-carboxamide inhibitors of the DNA-repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) is reported. The introduction of an amine substituent at the 2-aryl position is not detrimental to activity, with most inhibitors exhibiting K-i values for PARP-1 inhibition in the low nanomolar range. Two compounds in this series were found to potentiate the cytotoxicity of the DNA-methylating agent temozolomide by 4-5-fold in a human colorectal cancer cell line. (C) 2004 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2004.03.017

文献信息

• SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS
  申请人：Penning D. Thomas

  公开号：US20070112047A1

  公开（公告）日：2007-05-17

  Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compounds of Formula (I).

  化合物的化学式(I)抑制PARP酶，可用于治疗与PARP相关的疾病或疾病。还披露了包含化合物的药物组合物的化学式(I)，包含化合物的治疗方法的方法的化学式(I)，以及包含化合物的PARP酶抑制方法的方法的化学式(I)。
• Synthesis and Evaluation of a New Generation of Orally Efficacious Benzimidazole-Based Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors as Anticancer Agents
  作者：Yunsong Tong、Jennifer J. Bouska、Paul A. Ellis、Eric F. Johnson、Joel Leverson、Xuesong Liu、Patrick A. Marcotte、Amanda M. Olson、Donald J. Osterling、Magdalena Przytulinska、Luis E. Rodriguez、Yan Shi、Nirupama Soni、Jason Stavropoulos、Sheela Thomas、Cherrie K. Donawho、David J. Frost、Yan Luo、Vincent L. Giranda、Thomas D. Penning

  DOI：10.1021/jm900697r

  日期：2009.11.12

  Small molecule inhibitors of PARP-1 have been pursued by various organizations as potential therapeutic agents either capable of sensitizing cytotoxic treatments or acting as stand-alone agents to combat cancer. As one of the strategies to expand our portfolio of PARP-1 inhibitors, we pursued unsaturated heterocycles to replace the saturated cyclic alpine derivatives appended to the benzimidazole core. Not only did a variety of these new generation compounds maintain high enzymatic potency, many of them also displayed robust cellular activity. For example, the enzymatic IC50 and cellular EC50 values were as low as 1 nM or below. Compounds 24 (EC50 = 3.7 nM) and 44 (EC50 = 7.8 nM), featuring an oxadiazole and a pyridine moiety, respectively, demonstrated balanced potency and PK profiles. In addition, these two molecules exhibited potent oral in vivo efficacy in potentiating the cytotoxic agent temozolomide in a B16F10 murine melanoma model.
• US7462724B2
  申请人：——

  公开号：US7462724B2

  公开（公告）日：2008-12-09
• US7595406B2
  申请人：——

  公开号：US7595406B2

  公开（公告）日：2009-09-29
• [EN] SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES ARE POTENT PARP INHIBITORS<br/>[FR] 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUES EFFICACES EN TANT QU'INHIBITEURS DE PARP
  申请人：ABBOTT LAB

  公开号：WO2007059230A2

  公开（公告）日：2007-05-24

  [EN] Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compounds of Formula (I).
  [FR] L'invention concerne des composés répondant à la formule (I) inhibant l'enzyme PARP et utiles dans le traitement d'une pathologie ou d'un trouble associé à PARP. L'invention concerne également des compositions pharmaceutiques comprenant des composés répondant à la formule (I), des procédés de traitement comprenant des composés répondant à la formule (I) et des procédés d'inhibition de l'enzyme PARP comprenant des composés répondant à la formule (I).